Trending Topic

5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

touchDERMATOLOGY coverage from EADV 2024: Twice-daily continuous application of ruxolitinib cream, a topical selective JAK1/JAK2 inhibitor, has been reported to be safe and effective in treating children with mild to moderate atopic dermatitis (AD) over an 8-week period in the TRuE-AD studies.1,2 In this interview, we talk with Dr Amy Paller from the Northwestern University […]

2024 AAD ANNUAL MEETING American Academy of Dermatology

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 9th 2024

San Diego Skyline

We’re looking forward to the upcoming 2024 AAD Annual Meeting which is taking place in San Diego between 8-12 March 2024. 

Promising attendees an opportunity to explore the latest technologies, treatments and products in the field of dermatology, we are excited to provide independent, expert video coverage of key data.

You can sign-up here to receive our AAD 2024 content, as well as future content, or follow the congress on social media using #AAD2024

Soon we’ll be sharing our exclusive interviews with industry experts, but in the meantime – explore our collection of video interviews from here.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup